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1. Data {#sec1}
=======

This dataset presented the *in silico* and structural analysis of the five newly discovered variations, namely c.187G \> A (p.E63K), c.585G \> C (p.Q195H), c.586A \> T (p.I196F), c.743G \> A (p.G248D), and c.1330G \> A (p.V444I) ([Fig. 1](#fig1){ref-type="fig"}), detected in the six Taiwanese G6PD deficient patients using Sanger Sequencing ([Table 1](#tbl1){ref-type="table"}).Fig. 1Detection of five new *G6PD* variations by Sanger sequencing. *G6PD* gene sequence showed the wild type sequence with variants of different individuals. (A) c.187G \> A in patient A397, (B) c.585G \> C in patient A367, (C) c.586A \> T in patient A 129, (D) c.743G \> A in patient A244 and (E) c.1330G \> A in patients A281 and A453. The red arrows showed substitution in a hemizygous state in the missense mutations observed.Fig. 1Table 1G6PD activity in newborn screening and following referral for patients carrying newly discovered *G6PD* variations.Table 1Patient NumberA129A244A281A367A397A453SexMaleMaleMaleMaleMaleMalePlace of BirthChanghuaChiayiTainanTainanPingtungTainanAge at newborn screening (day)222233G6PD activity in newborn screening (U/gHb)[a](#tbl1fna){ref-type="table-fn"}0.25.55.31.75.75.1Age when confirmed (day)34922151411Confirmed G6PD activity (U/gHb)[b](#tbl1fnb){ref-type="table-fn"}0.16.15.50.28.66.5Variation foundc.586A \> Tc.743G \> Ac.1330G \> Ac.585G \> Cc.187G \> Ac.1330G \> A[^3][^4]

The comparison sequence of these variants in G6PD protein of different species [@bib2], including *Homo sapiens*, *Mus musculus*, *Danio rerio* (zebrafish), *Drosophila melanogaster* (fruit fly), and *Caenorhabditis elegans* were presented in [Fig. 2](#fig2){ref-type="fig"}. The *in silico* analysis using SIFT [@bib3], PolyPhen-2 [@bib3], Mutation Taster [@bib4] and Slicing Finder [@bib5] softwares, as well as the conservation between species and allele frequency in Taiwanese population [@bib6] were summarized in [Table 2](#tbl2){ref-type="table"}. Furthermore, the amino acid alterations were presented in the functional domains [@bib7] ([Fig. 3](#fig3){ref-type="fig"}) and in partial 3D model of G6PD [@bib8] ([Fig. 4](#fig4){ref-type="fig"}). The structure of the resultant mutant G6PD protein were analyzed by HOPE, Have yOur Protein Explained [@bib9] ([Table 3](#tbl3){ref-type="table"}).Fig. 2The similarity alignment of G6PD proteins across different species. The red characters show the corresponding positions of the five substitutions between species whereas the conserved residues were outlined in green box. The species abbreviations are: *D. melanogaster*, *Drosophila melanogaster*; *C. elegans*, *Caenorhabditis elegans.*Fig. 2Table 2The severity prediction for five newly discovered *G6PD* missense variations.Table 2Nucleotide substitutionAmino acid substitutionSIFTPolyPhen-2Mutation TasterSplicing finderConservation[a](#tbl2fna){ref-type="table-fn"}Allele Frequency[b](#tbl2fnb){ref-type="table-fn"}Predicted Class[c](#tbl2fnc){ref-type="table-fn"}c.187G \> Ap.E63KToleratedBenignDisease causingPotential alterationModerately\<2/1417[d](#tbl2fnd){ref-type="table-fn"}III-IVc.585G \> Cp.Q195HDamagingProbably damagingDisease causingPotential alterationHighly\<1/1000IIc.586A \> Tp.I196FDamagingProbably damagingDisease causingPotential alterationHighly\<1/1000IIc.743G \> Ap.G248DDamagingProbably damagingDisease causingProbably no impactHighly\<1/1000IIIc.1330G \> Ap.V444IToleratedPossibly damagingDisease causingPotential alterationHighly\<1/1000III[^5][^6][^7][^8]Fig. 3Schematic representation of alterations in G6PD coding regions and protein functional domains. (A) The coding region of the *G6PD* gene containing 13 exons. (B) The G6PD protein of 515 amino acids contains two binding domains, namely NAD(P)-binding domain (blue box, amino acids 25--210) and *C*-terminal domain (green box, amino acids 212--503), and two binding sites, namely NAD(P) binding site (left red box, amino acids 38--44) and G6P-binding site (middle red box, amino acids 198--206), and one dimer interface (right red box, amino acids 380--425). The five mutations were highlighted in black in the coding region and protein domains.Fig. 3Fig. 4Close-up views of the ribbon diagram of human G6PD as generated by Swiss PDB viewer. (A) The 3D model structure of G6PD closed to the G6P-binding site, and the Glu63, Gln195, Ile196 and Val444 residuals. (B) A close-up view of G6PD protein contains the NAD(P)-binding site and Gly248 residual. The G6P- and NAD(P)-binding sites were highlighted in cyan, while the residuals were presented in red.Fig. 4Table 3Structure prediction of the *G6PD* variations by HOPE algorithm.Table 3MutantsStructure prediction by HOPE algorithm[a](#tbl3fna){ref-type="table-fn"}p.E63KThe wide-type residue forms a salt bridge with arginine at position 104. The difference in charge will disturb the ionic interaction made by the original, wild-type residue.p.Q195HThe wild-type residue forms a hydrogen bond with arginine at position 192. The size difference between wild-type and mutant residue makes that the new residue is not in the correct position to make the same hydrogen bond as the original wild-type residue did.p.I196FThe mutant residue is bigger than the wild-type residue and is located in a domain that is important for the activity of the protein and in contact with residues in another domain. The mutation can affect this interaction and as such affect protein function.p.G248DThe wild-type residue is a glycine, the most flexible of all residues. This flexibility might be necessary for the protein\'s function. Mutation of this glycine can abolish this function.p.V444IThe mutant residue is bigger than the wild-type residue and is located in a domain that is important for binding of other molecules. The mutation might affect this interaction and thereby disturb signal transfer from binding domain to the activity domain.[^9]

2. Experimental design, materials and methods {#sec2}
=============================================

2.1. Mutation identification: sanger sequencing {#sec2.1}
-----------------------------------------------

In 500 G6PD-deficient male newborns detected by G6PD enzyme activity assay [@bib10], nine of which do not carry any of the 21 common mutations described in Taiwan and Southeast Asia using multiplex SNaPshot assay [@bib1]. Their dried blood spots used in newborn screening were subsequently subjected to mutational analysis by sequencing. The whole coding exons and exon-intron boundary sequences of *G6PD* gene were amplified and analyzed by forward and reverse Sanger sequencing. Putative mutations were confirmed by sequencing of an independent PCR product. The study protocol was reviewed and approved by the Institutional Review Board of Taipei City Hospital, Taiwan.

2.2. Sequence alignments between species {#sec2.2}
----------------------------------------

Conservation of the peptide sequence around the affected residues was assessed by alignment of orthologous and human G6PD sequences with ClustalW2, [@bib2].

2.3. Severity prediction and allele frequency in population {#sec2.3}
-----------------------------------------------------------

Different online algorithms were used to predict the functional consequences of the five variants. The *in silico* analyses were performed using the SIFT [@bib3], PolyPhen-2 [@bib3], MutationTaster2 [@bib4], and Human Splicing Finder [@bib5] programs. Furthermore, the allele frequency of the alterations in Taiwanese population was listed as provided in Taiwan Biobank [@bib6].

2.4. Distribution of mutations along the coding region and protein sequence {#sec2.4}
---------------------------------------------------------------------------

Distribution of alterations was highlighted in the coding region and the functional domains [@bib7]. The A at the ATG translational initiation codon was numbered as 1 in reference accession number [NM_001042351](ncbi-n:NM_001042351){#intref0015}. The amino acid numbers were counted from the *N*-terminal Met of human G6PD protein.

2.5. 3D structure model of wide type G6PD protein {#sec2.5}
-------------------------------------------------

The 3D structure of *G6PD* variations observed in this study were presented based on the X-ray crystal structure available at the Protein Data Bank from human G6PD protein (PDB code [1QKI](pdb:1QKI){#intref0020}) [@bib8].

2.6. Prediction of structural effects of variations {#sec2.6}
---------------------------------------------------

When protein structure is important to predict the effects of variants [@bib11], effect of mutations over G6PD protein structure was determined using HOPE (Have yOur Protein Explained) software [@bib9].
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